Comparison of antiarrhythmics used in patients with paroxysmal atrial fibrillation

Subanalysis of J-RHYTHM study

Yoshiyasu Aizawa, Shun Kosaka, Shinya Suzuki, Hirotsugu Atarashi, Shiro Kamakura, Masayuki Sakurai, Haruaki Nakaya, Masahiko Fukatani, Hideo Mitamura, Tsutomu Yamazaki, Takeshi Yamashita, Satoshi Ogawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study demonstrated the benefit of rhythm-control compared with rate-control in Japanese patients with paroxysmal atrial fibrillation (AF), according to AF-specific quality of life scores. However, detailed information on prescribed antiarrhythmic agents remains unclear. Methods and Results: Data for 419 patients enrolled in the rhythm-control arm of J-RHYTHM were analyzed. The primary endpoint was defined as a composite of total mortality, cerebral infarction, embolism, bleeding, heart failure, and physical/psychological disability. The secondary endpoint was recurrence of AF. The clinical outcome according to choice of initial antiarrhythmic agent (AA) was assessed by Kaplan-Meier survival curve, and further adjusted by Cox-regression hazard model. The primary endpoint occurred in 16.9%, 6.7%, 15.8% and 23.3% of patients assigned to class Ia, Ib, Ic and III agents (P=0.359). The rate of AF recurrence was significantly higher in patients taking a class III drug (Ia, Ib, Ic, III=20.3, 23.3, 29.1, 50.0%; P=0.002). However, after adjustment for other clinical variables, the choice of AA was not associated with recurrence of AF (class I vs III, P=0.15). Conclusions: The incidence of each endpoint did not differ according to the choice of AA. The class III drugs seemed to lower the sinus rhythm maintenance rate, which might be confounded by other comorbid conditions.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalCirculation Journal
Volume74
Issue number1
DOIs
Publication statusPublished - 2010 Jan

Fingerprint

Atrial Fibrillation
Recurrence
Intracranial Embolism
Cerebral Infarction
Kaplan-Meier Estimate
Proportional Hazards Models
Pharmaceutical Preparations
Heart Failure
Maintenance
Quality of Life
Hemorrhage
Psychology
Mortality
Incidence

Keywords

  • Antiarrhythmic drugs
  • Atrial fibrillation
  • Rhythm control

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of antiarrhythmics used in patients with paroxysmal atrial fibrillation : Subanalysis of J-RHYTHM study. / Aizawa, Yoshiyasu; Kosaka, Shun; Suzuki, Shinya; Atarashi, Hirotsugu; Kamakura, Shiro; Sakurai, Masayuki; Nakaya, Haruaki; Fukatani, Masahiko; Mitamura, Hideo; Yamazaki, Tsutomu; Yamashita, Takeshi; Ogawa, Satoshi.

In: Circulation Journal, Vol. 74, No. 1, 01.2010, p. 71-76.

Research output: Contribution to journalArticle

Aizawa, Y, Kosaka, S, Suzuki, S, Atarashi, H, Kamakura, S, Sakurai, M, Nakaya, H, Fukatani, M, Mitamura, H, Yamazaki, T, Yamashita, T & Ogawa, S 2010, 'Comparison of antiarrhythmics used in patients with paroxysmal atrial fibrillation: Subanalysis of J-RHYTHM study', Circulation Journal, vol. 74, no. 1, pp. 71-76. https://doi.org/10.1253/circj.CJ-09-0367
Aizawa, Yoshiyasu ; Kosaka, Shun ; Suzuki, Shinya ; Atarashi, Hirotsugu ; Kamakura, Shiro ; Sakurai, Masayuki ; Nakaya, Haruaki ; Fukatani, Masahiko ; Mitamura, Hideo ; Yamazaki, Tsutomu ; Yamashita, Takeshi ; Ogawa, Satoshi. / Comparison of antiarrhythmics used in patients with paroxysmal atrial fibrillation : Subanalysis of J-RHYTHM study. In: Circulation Journal. 2010 ; Vol. 74, No. 1. pp. 71-76.
@article{25e9f60e8d2d4d2d86f734036a8e5fa0,
title = "Comparison of antiarrhythmics used in patients with paroxysmal atrial fibrillation: Subanalysis of J-RHYTHM study",
abstract = "Background: The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study demonstrated the benefit of rhythm-control compared with rate-control in Japanese patients with paroxysmal atrial fibrillation (AF), according to AF-specific quality of life scores. However, detailed information on prescribed antiarrhythmic agents remains unclear. Methods and Results: Data for 419 patients enrolled in the rhythm-control arm of J-RHYTHM were analyzed. The primary endpoint was defined as a composite of total mortality, cerebral infarction, embolism, bleeding, heart failure, and physical/psychological disability. The secondary endpoint was recurrence of AF. The clinical outcome according to choice of initial antiarrhythmic agent (AA) was assessed by Kaplan-Meier survival curve, and further adjusted by Cox-regression hazard model. The primary endpoint occurred in 16.9{\%}, 6.7{\%}, 15.8{\%} and 23.3{\%} of patients assigned to class Ia, Ib, Ic and III agents (P=0.359). The rate of AF recurrence was significantly higher in patients taking a class III drug (Ia, Ib, Ic, III=20.3, 23.3, 29.1, 50.0{\%}; P=0.002). However, after adjustment for other clinical variables, the choice of AA was not associated with recurrence of AF (class I vs III, P=0.15). Conclusions: The incidence of each endpoint did not differ according to the choice of AA. The class III drugs seemed to lower the sinus rhythm maintenance rate, which might be confounded by other comorbid conditions.",
keywords = "Antiarrhythmic drugs, Atrial fibrillation, Rhythm control",
author = "Yoshiyasu Aizawa and Shun Kosaka and Shinya Suzuki and Hirotsugu Atarashi and Shiro Kamakura and Masayuki Sakurai and Haruaki Nakaya and Masahiko Fukatani and Hideo Mitamura and Tsutomu Yamazaki and Takeshi Yamashita and Satoshi Ogawa",
year = "2010",
month = "1",
doi = "10.1253/circj.CJ-09-0367",
language = "English",
volume = "74",
pages = "71--76",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "1",

}

TY - JOUR

T1 - Comparison of antiarrhythmics used in patients with paroxysmal atrial fibrillation

T2 - Subanalysis of J-RHYTHM study

AU - Aizawa, Yoshiyasu

AU - Kosaka, Shun

AU - Suzuki, Shinya

AU - Atarashi, Hirotsugu

AU - Kamakura, Shiro

AU - Sakurai, Masayuki

AU - Nakaya, Haruaki

AU - Fukatani, Masahiko

AU - Mitamura, Hideo

AU - Yamazaki, Tsutomu

AU - Yamashita, Takeshi

AU - Ogawa, Satoshi

PY - 2010/1

Y1 - 2010/1

N2 - Background: The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study demonstrated the benefit of rhythm-control compared with rate-control in Japanese patients with paroxysmal atrial fibrillation (AF), according to AF-specific quality of life scores. However, detailed information on prescribed antiarrhythmic agents remains unclear. Methods and Results: Data for 419 patients enrolled in the rhythm-control arm of J-RHYTHM were analyzed. The primary endpoint was defined as a composite of total mortality, cerebral infarction, embolism, bleeding, heart failure, and physical/psychological disability. The secondary endpoint was recurrence of AF. The clinical outcome according to choice of initial antiarrhythmic agent (AA) was assessed by Kaplan-Meier survival curve, and further adjusted by Cox-regression hazard model. The primary endpoint occurred in 16.9%, 6.7%, 15.8% and 23.3% of patients assigned to class Ia, Ib, Ic and III agents (P=0.359). The rate of AF recurrence was significantly higher in patients taking a class III drug (Ia, Ib, Ic, III=20.3, 23.3, 29.1, 50.0%; P=0.002). However, after adjustment for other clinical variables, the choice of AA was not associated with recurrence of AF (class I vs III, P=0.15). Conclusions: The incidence of each endpoint did not differ according to the choice of AA. The class III drugs seemed to lower the sinus rhythm maintenance rate, which might be confounded by other comorbid conditions.

AB - Background: The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study demonstrated the benefit of rhythm-control compared with rate-control in Japanese patients with paroxysmal atrial fibrillation (AF), according to AF-specific quality of life scores. However, detailed information on prescribed antiarrhythmic agents remains unclear. Methods and Results: Data for 419 patients enrolled in the rhythm-control arm of J-RHYTHM were analyzed. The primary endpoint was defined as a composite of total mortality, cerebral infarction, embolism, bleeding, heart failure, and physical/psychological disability. The secondary endpoint was recurrence of AF. The clinical outcome according to choice of initial antiarrhythmic agent (AA) was assessed by Kaplan-Meier survival curve, and further adjusted by Cox-regression hazard model. The primary endpoint occurred in 16.9%, 6.7%, 15.8% and 23.3% of patients assigned to class Ia, Ib, Ic and III agents (P=0.359). The rate of AF recurrence was significantly higher in patients taking a class III drug (Ia, Ib, Ic, III=20.3, 23.3, 29.1, 50.0%; P=0.002). However, after adjustment for other clinical variables, the choice of AA was not associated with recurrence of AF (class I vs III, P=0.15). Conclusions: The incidence of each endpoint did not differ according to the choice of AA. The class III drugs seemed to lower the sinus rhythm maintenance rate, which might be confounded by other comorbid conditions.

KW - Antiarrhythmic drugs

KW - Atrial fibrillation

KW - Rhythm control

UR - http://www.scopus.com/inward/record.url?scp=75149195904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149195904&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-09-0367

DO - 10.1253/circj.CJ-09-0367

M3 - Article

VL - 74

SP - 71

EP - 76

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 1

ER -